Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
Early P 1 (1)
P 2 (2)

Trial Status

Terminated1
Recruiting1
Not Yet Recruiting1
Unknown1
Enrolling By Invitation1

Clinical Trials (5)

Showing 5 of 5 trials
NCT05307679Phase 2TerminatedPrimary

A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

NCT03836300Not ApplicableEnrolling By Invitation

Parent and Infant Inter(X)Action Intervention (PIXI)

NCT07079696Phase 2Not Yet RecruitingPrimary

Investigating the Therapeutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Patients With 15q11-13 Duplication Syndrome

NCT06353620Recruiting

Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With Epilepsy

NCT05281965Early Phase 1Unknown

A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome

Showing all 5 trials

Research Network

Activity Timeline